Search research articles
Contact Us
Filters
Showing results (1-10 of 126) with videos related to
Page
of 13
Sort By:
European Urology
|
April 17, 2018
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8
Francesco Massari, Vincenzo Di Nunno
The Lancet. Oncology
|
January 20, 2019
CheckMate 214 patient-reported outcomes: listening to our patients
Francesco Massari, Vincenzo Di Nunno
Lancet (London, England)
|
December 23, 2017
Atezolizumab for platinum-treated metastatic urothelial carcinoma
Francesco Massari, Vincenzo Di Nunno
Expert Review of Anticancer Therapy
|
May 7, 2020
How to face cancer treatment in the COVID-19 era
Alba A Brandes, Vincenzo Di Nunno
The Lancet. Oncology
|
September 8, 2018
Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?
Vincenzo Di Nunno, Matteo Santoni, Francesco Massari
European Urology
|
November 8, 2017
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8
Francesco Massari, Vincenzo Di Nunno, Andrea Ardizzoni
Translational Cancer Research
|
February 4, 2022
N-Myc a key gene promoting a worst prostate cancer progression
Vincenzo Di Nunno, Veronica Mollica, Francesco Massari
Current Opinion in Oncology
|
September 9, 2024
Achievements of international rare cancers networks and consortia in the neuro-oncology field
Vincenzo Di Nunno, Enrico Franceschi, Ahmed Idbaih
European Urology Oncology
|
June 16, 2019
Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?
Francesco Massari, Vincenzo Di Nunno, Matteo Santoni
Chinese Clinical Oncology
|
July 9, 2019
Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma
Veronica Mollica, Vincenzo Di Nunno, Francesco Massari
Page
of 13
Search research articles
Search
Showing results (1-10 of 126) with videos related to
Sort By:
Page
of 13
European Urology
|
April 17, 2018
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8
Francesco Massari, Vincenzo Di Nunno
The Lancet. Oncology
|
January 20, 2019
CheckMate 214 patient-reported outcomes: listening to our patients
Francesco Massari, Vincenzo Di Nunno
Lancet (London, England)
|
December 23, 2017
Atezolizumab for platinum-treated metastatic urothelial carcinoma
Francesco Massari, Vincenzo Di Nunno
Expert Review of Anticancer Therapy
|
May 7, 2020
How to face cancer treatment in the COVID-19 era
Alba A Brandes, Vincenzo Di Nunno
The Lancet. Oncology
|
September 8, 2018
Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?
Vincenzo Di Nunno, Matteo Santoni, Francesco Massari
European Urology
|
November 8, 2017
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8
Francesco Massari, Vincenzo Di Nunno, Andrea Ardizzoni
Translational Cancer Research
|
February 4, 2022
N-Myc a key gene promoting a worst prostate cancer progression
Vincenzo Di Nunno, Veronica Mollica, Francesco Massari
Current Opinion in Oncology
|
September 9, 2024
Achievements of international rare cancers networks and consortia in the neuro-oncology field
Vincenzo Di Nunno, Enrico Franceschi, Ahmed Idbaih
European Urology Oncology
|
June 16, 2019
Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?
Francesco Massari, Vincenzo Di Nunno, Matteo Santoni
Chinese Clinical Oncology
|
July 9, 2019
Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma
Veronica Mollica, Vincenzo Di Nunno, Francesco Massari
Page
of 13